Approval · Notice of Compliance 28318 · 2022
CLEVIPREX: Notice of Compliance 28318
Issued June 3, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28318
- Date
- June 3, 2022
- Company
- Chiesi Farmaceutici S.P.A.Parma, --, Italy
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety updates to the Product Monograph Conversion of the Product Monograph to the 2020 format Update to Package Insert Update to the inner and outer labels
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CLEVIPREX | Not yet assigned | — |
Medicinal ingredients
- CLEVIDIPINE 0.5 MG per ML